Scientific Reports, 2017 Mice lacking secreted IgM (sIgM −/−) antibodies display abnormal splenic B cell development, which results in increased marginal zone and decreased follicular B cell numbers. However, the mechanism by which sIgM exhibit this effect is unknown.
Dimitrios Tsiantoulas +6 more
doaj +1 more source
DNA methyltransferase inhibitors in hematological malignancies and solid tumors
International Journal of Cancer, Volume 158, Issue 2, Page 433-461, 15 January 2026.Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Valentin Wenger +3 more
wiley +1 more source
Functional interaction between CD180 Toll-like receptor (TLR) and B cell receptor (BCR) in the biology of Chronic Lymphocytic Leukaemia (CLL) [PDF]
, 2017 Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in the western world and remains incurable. It is driven by as yet unknown (auto)antigens via the B cell receptor (BCR) and growth, survival and expansion signals it receives from the ...
Rajakaruna, A., Rajakaruna, A.
core
Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity [PDF]
, 2003 The Tec family member Bruton's tyrosine kinase (Btk) is a cytoplasmic protein tyrosine kinase that transduces signals from the pre-B and B cell receptor (BCR).
Dahlenborg, K. +4 more
core +1 more source
Cancer ReportsBackground Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterised by low platelet count. Treatment discontinuation or heterogeneity in the pathogenesis of ITP heightens the occurrence of relapsed or refractory ITP.
Bingjie Ding +7 more
doaj +1 more source
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
PLoS ONE, 2023 Bruton’s tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-
David Y. Lin, Amy H. Andreotti
doaj
Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma
Medicine in Novel Technology and DevicesExploring novel therapeutic targets of Diffuse large B cell lymphoma (DLBCL) to overcome its resistance to Bruton's Tyrosine Kinase (BTK) inhibitors is a key topic.
Zhuojun Liu +5 more
doaj +1 more source
Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. [PDF]
PLoS One, 2023 Kozaki R +8 more
europepmc +1 more source
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor. [PDF]
Mult Scler, 2023 Bar-Or A +9 more
europepmc +1 more source
Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy. [PDF]
PLoS One, 2022 Park HY +5 more
europepmc +1 more source